Who was studied, and how
Five numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 8 other studies
190people in the Efficacy, Safety & Tolerability of Combination of Ertugliflozin and Sitagliptin in Patients With Type II Diabetes Mellitus trial, from 2022
of them with hypertension, in this paper
Among individuals with type 2 diabetes mellitus, the trial randomly assignedassigned by chance
SGLT2
control (implied)
May have lowered diastolic BP−1.46
May have lowered body weight−1.88
May have lowered serum triglycerides−2.08
randomised · one subgroupthe abstract, start to end
… for the effect on diastolic BP was -1.46 mm Hg (95% CI -1.82 to -1.09).
… the effect of SGLT2 on body weight was -1.88 kg (95% CI -2.11 to -1.66) …
… triglycerides and total cholesterol were -2.08 mg/dL (95% CI -2.51 to -1.64) and 0.77 mg/dL (95% CI 0.33-1.21), …
… with SGLT2 (weighted mean difference -2.46 mm Hg [95% CI -2.86 to -2.06]).
← favours treatmentfavours comparator →
could be chanceDiastolic BPSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
−1.46−1.82 to −1.09
Body weightSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
−1.88−2.11 to −1.66
Serum triglyceridesSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
−2.08−2.51 to −1.64
Systolic BPSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
−2.46−2.86 to −2.06
Total cholesterolSGLT2 vs control (implied), in individuals with type 2 diabetes mellitus
0.770.33–1.21
SGLT2 inhibitorsBody weight & compositionLipidsBlood pressure
SGLT2 inhibitors × lipidshelps?replicated
unlikelylikely
1.00not counted
SGLT2 inhibitors × blood pressurehelps?settled
unlikelylikely
0.88not counted
SGLT2 inhibitors × body weight & compositionhelps?settled
unlikelylikely
0.98not counted
← favours comparatorfavours treatment →
1 / 6